NWNoritaka Wakui

Noritaka Wakui

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Noritaka Wakui has a total of 101 co-authors. Here are the top co-authors by number of shared publications:

  • Hidenari Nagai

    Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan

    13 shared publications
  • Yu Ogino

    Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan

    10 shared publications
  • Yasukiyo Sumino

    Department of Gastroenterology and Hepatology, Japan Community Health Care Organization (JCHO) Tokyo Kamata Hospital, Tokyo, Japan

    9 shared publications
  • Yoshinori Igarashi

    Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan

    9 shared publications
  • Yasushi Matsukiyo

    Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan

    7 shared publications
  • Kojiro Kobayashi

    Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan

    6 shared publications

Latest Publications

  • Open Access

    Pemafibrate therapy increases serum zinc levels in patients with metabolic dysfunction–associated steatohepatitis: a prospective study

    by Noritaka Wakui, Yu Ogino, Hideki Nagumo, Naho Watanabe, Kunihide Mouri, Naoyuki Yoshimine, Kojiro Kobayashi, Takanori Mukozu, Teppei Matsui, Takahisa Matsuda

    Background: Zinc deficiency is common in chronic liver disease and is closely associated with the progression of hepatic fibrosis and metabolic dysfunction. Although pemafibrate, a selective peroxisome proliferator-activated receptor alpha modulator, has had beneficial effects on lipid metabolism, inflammation, and oxidative stress, its impact on zinc metabolism in patients with metabolic dysfunction-associated steatohepatitis (MASH) remains unclear. Methods: This prospective study involved patients with biopsy-confirmed MASH complicated by hypertriglyceridemia (fasting triglycerides ≥ 150 mg/dL) who were treated with pemafibrate (0.2 mg twice daily). Serum zinc levels were evaluated at baseline and at 6, 12, 24, and 36 months after initiation of treatment. Subgroup analyses were performed according to cirrhosis status and baseline serum zinc level (< 80 µg/dL vs. ≥80 µg/dL). Changes in liver-related biochemical parameters and albumin levels were also assessed. Results: Twenty-six patients (mean age 56.3 ± 12.6 years; 17 men) were followed for 36 months. Serum zinc levels had increased significantly at 6 months after initiation of pemafibrate and remained significantly elevated through to 36 months. Patients without cirrhosis showed a sustained increase in serum zinc levels throughout the observation period, whereas those with cirrhosis had a delayed and transient response. The serum zinc level increased earlier in patients with zinc deficiency at baseline than in those with a preserved level at baseline. Serum albumin levels increased significantly up to 24 months but not up to 36 months, whereas serum zinc levels remained elevated, suggesting the involvement of albumin-independent mechanisms. Pemafibrate therapy was also associated with significant improvements in triglycerides, liver enzymes, and fibrosis-related markers. Conclusions: Pemafibrate therapy was associated with a significant and sustained increase in the serum zinc level in patients with hypertriglyceridemia-related MASH, even in the absence of zinc supplementation. However, given the small sample size, the absence of a control group, and the single-arm study design, future large-scale multicenter studies that include a greater number of patients are warranted.

  • The Bubble-Destruction Curve Obtained Using Contrast-Enhanced Ultrasound is Useful for Assessing Liver Fibrosis and Identifying At-risk MASH in Patients With MASLD

    by Noritaka Wakui, Yu Ogino, Naohisa Kamiyama, Takuma Oguri, Tomoya Uchimura, Takahide Kudo, Kenichi Maruyama, Hideki Nagumo, Naoyuki Yoshimine, Kunihide Mouri, et al.


  • Comparison of strain elastography and shear wave elastography in diagnosis of fibrosis in nonalcoholic fatty liver disease

    by Yu Ogino, Noritaka Wakui, Hidenari Nagai, Takahisa Matsuda

    Purpose To reveal the ability of S-Map strain elastography to diagnose fibrosis in nonalcoholic fatty liver disease (NAFLD) and to compare its diagnostic ability with that of shear wave elastography (SWE). Methods Participants were patients with NAFLD who were scheduled to undergo liver biopsy at our institution between 2015 and 2019. A GE Healthcare LOGIQ E9 ultrasound system was used. For S-Map, the right lobe of the liver was visualized in the section where the heartbeat was detected by right intercostal scanning, a 4 × 2-cm region of interest (ROI) was defined at 5 cm from the liver surface, and ROI strain images were acquired. Measurements were repeated six times, with the average taken as the S-Map value. Correlations of S-Map and SWE values with fibrosis stage determined by liver biopsy were analyzed using multiple comparisons. The diagnostic performance of S-Map for fibrosis staging was assessed using receiver operating characteristic curves. Results In total, 107 patients (65 men, 42 women; mean age 51 ± 14 years) were analyzed. The S-Map value by fibrosis stage was 34.4 ± 10.9 for F0, 32.9 ± 9.1 for F1, 29.5 ± 5.6 for F2, 26.7 ± 6.0 for F3, and 22.8 ± 4.19 for F4. By fibrosis stage, the SWE value was 1.27 ± 0.25 for F0, 1.39 ± 0.20 for F1, 1.59 ± 0.20 for F2, 1.64 ± 0.17 for F3, and 1.88 ± 0.19 for F4. The diagnostic performance of S-Map (measured by area under the curve) was 0.75 for F2, 0.80 for F3, and 0.85 for F4. The diagnostic performance of SWE (measured by area under the curve) was 0.88 for F2, 0.87 for F3, and 0.92 for F4. Conclusion S-Map strain elastography was inferior to SWE in terms of ability to diagnose fibrosis in NAFLD.


  • Open Access

    Usefulness of partial splenic embolization for left-sided portal hypertension in a patient with a pancreatic neuroendocrine neoplasm: a case report and review of the literature

    by Teppei Matsui, Hidenari Nagai, Makoto Amanuma, Kojiro Kobayashi, Yu Ogino, Takanori Mukozu, Noritaka Wakui, Naoki Okano, Yoshinori Kikuchi, Takahisa Matsuda, et al.

    Left-side portal hypertension (LSPH) is caused by isolated obstruction of the splenic vein and is associated with esophagogastric varices that extend from the lower esophagus to the greater curvature of the gastric body. Here, we report on a 74-year-old man with a pancreatic neuroendocrine neoplasm (NEN) in the pancreatic tail with multiple liver metastases. We decided that partial splenic embolization (PSE) was the best course of treatment to prevent rupture of the gastric varices, which were classified as markedly enlarged, nodular, or tumor-shaped and showed erosion of the mucosa. After PSE, the patient had no major complications and was discharged. At 3 and 6 months after the procedure, esophagogastroduodenoscopy and enhanced computerized tomography showed that the gastric varices had improved. This case demonstrates the usefulness of PSE for LSPH in patients with unresected pancreatic NEN.


  • Arrival-Time Parametric Imaging in Contrast-Enhanced Ultrasound for Diagnosing Fibrosis in Primary Biliary Cholangitis

    by Naoyuki Yoshimine, Noritaka Wakui, Hidenari Nagai, Yoshinori Igarashi

    Liver biopsy is usually required for diagnosing fibrosis in primary biliary cholangitis (PBC), but contrast-enhanced ultrasonography (CEUS) is a possible alternative. The aim of this study was to investigate arrival-time parametric imaging (At-PI) in for diagnosing fibrosis in PBC. Forty-eight patients (male/female, 8/40; mean age, 60 ± 13 years) with PBC diagnosed by liver biopsy underwent CEUS during 2009–2019. Of these, 27 who also underwent shear wave elastography (SWE) were further analyzed. Perflubutane was intravenously injected and CEUS performed. Contrast dynamics of hepatic segment V and the right kidney were recorded and At-PI generated. The ratio of red indicating contrast arrival time <5 seconds to the entire liver contrast-enhanced area was calculated and compared with shear wave velocity (Vs) measured by SWE by fibrosis stage (F0–F3), bile duct loss score, cholangitis activity, hepatitis activity (HA0–HA3), and disease stage, as determined by liver biopsy. Ratio of red significantly differed between F0 and F2–F3 and between F1 and F2–F3. Using ratio of red to diagnose ≥F1 (≥F2), area under the receiver operating characteristic curve was 0.77 (0.92) (cutoff, 36.7% [47.1%]; sensitivity, 0.75 [0.92]; specificity, 0.82 [0.81]). At-PI was useful for diagnosing fibrosis, especially F2 or worse, in PBC, suggesting that At-PI can correctly diagnose fibrosis regardless of hepatic inflammation.


  • Open Access

    The ultrasound‐guided attenuation parameter is useful in quantification of hepatic steatosis in non‐alcoholic fatty liver disease

    by Yu Ogino, Noritaka Wakui, Hidenari Nagai, Yoshinori Igarashi

    Aim: To determine the utility of the ultrasound‐guided attenuation parameter (UGAP) for quantifying hepatic steatosis in non‐alcoholic fatty liver disease (NAFLD).Methods: Subjects were 84 patients with NAFLD (53 men, 31 women; mean age 54 [20–81] years) who underwent liver biopsy and ultrasonography using a GE LOGIQ E9 system and C1‐6 probe at our hospital between 2017 and 2020. B‐Mode imaging of segment V in the liver was acquired and echo attenuation was assessed using UGAP. Steatosis score (S0: P < 0.01), demonstrating a significant increase with steatosis score. Receiver operating characteristic analysis showed good diagnostic performance of UGAP for patients with steatosis score ≥1, ≥2, and ≥3 (AUROC = 0.94, 0.95, and 0.88, respectively). Liver fat content (%) from liver specimens and AC (r = 0.81, P < 0.01) showed a significant positive correlation.Conclusion: UGAP is useful for quantifying hepatic steatosis in patients with NAFLD.


  • Open Access

    Usefulness of virtual touch tissue quantification for predicting the presence of esophageal varices in patients with liver cirrhosis

    by Teppei Matsui, Hidenari Nagai, Gou Watanabe, Naoyuki Yoshimine, Makoto Amanuma, Kojiro Kobayashi, Yuu Ogino, Takanori Mukozu, Yasushi Matsukiyo, Yasuko Daido, et al.

    Background and Aim: Measuring the hepatic venous pressure gradient (HVPG) is an established technique to detect increased portal pressure and predict the presence of esophageal varices (EVs); however, the risk of the test is greater than the information it provides. This study aimed to clarify the usefulness of virtual touch tissue quantification (VTQ), which assesses liver stiffness, in predicting the presence of EVs in patients with liver cirrhosis by comparing it with HVPG. Methods: Two hundred seventeen patients with liver cirrhosis underwent VTQ, HVPG measurement, and upper endoscopy. Patients were divided into three groups: group V, hepatitis C virus liver cirrhosis (n = 40); group A, alcoholic liver cirrhosis (n = 116); and group N, other liver cirrhosis (n = 61). In each group, we performed linear regression analysis of VTQ and HVPG data. The accuracy of VTQ and HVPG measurement in predicting the presence of EVs and high-risk EVs (EV category F2 and F3) was assessed by area under the receiver operating characteristic curve (AUROC). Results: VTQ was significantly correlated with the HVPG in the whole patients and in each group, and both VTQ and HVPG values were significantly higher in patients with EVs and high-risk EVs than in those without. The AUROC for the presence of EVs for VTQ was 0.76 in the whole sample, 0.76 in group V, 0.79 in group A, and 0.67 in group N; and for HVPG, 0.92, 0.94, 0.93, and 0.88, respectively. For VTQ, the AUROC for the presence of high-risk EVs was 0.78 in the whole sample, 0.78 in group V, 0.73 in group A, and 0.73 in group N; and for HVPG, it was 0.85, 0.82, 0.85, and 0.82, respectively. Conclusion: VTQ was reliable at predicting the presence of EVs and high-risk EVs. Therefore, we propose that VTQ is a useful, noninvasive tool for predicting the presence of EVs in daily medical care.


  • Open Access

    Arrival-Time Parametric Imaging in Contrast-Enhanced Ultrasound for Diagnosing Fibrosis in Primary Biliary Cholangitis

    by Naoyuki Yoshimine, Noritaka Wakui, Hidenari Nagai, Yoshinori Igarashi

    Background: To investigate arrival-time parametric imaging (At-PI) in contrast-enhanced ultrasonography (CEUS) for diagnosing fibrosis in primary biliary cholangitis (PBC). Methods: Participants were 48 patients (male/female: 8/40; mean age, 60 ± 13 years) with PBC diagnosed by liver biopsy who underwent CEUS during 2009-2019. Of these, 27 (male/female: 4/23; mean age, 61 ± 13 years) who also underwent shear wave elastography (SWE) were further analyzed. SonazoidTM was intravenously injected and CEUS performed. Contrast dynamics of hepatic segment V and the right kidney were recorded. At-PI were generated from the recorded video clips. Contrast arrival time Results: ROR significantly differed between F0 and F2-F3 and between F1 and F2-3. Using ROR to diagnose ³F1 (³F2), area under the receiver operating characteristic curve (AUROC) was 0.77 (0.92) (cutoff, 36.7% [47.1%]; sensitivity, 0.75 [0.92]; specificity, 0.82 [0.81]). Vs significantly differed between F0 and F1, F0 and F2-3, and HA0 and HA1. For diagnosing ³F1 (³F2), Vs had AUROC of 0.84 (0.80) (cutoff, 1.23 m/s [1.40 m/s]; sensitivity, 0.75 [0.60]; specificity, 0.82 [0.86]).Conclusions: At-PI was useful for diagnosing fibrosis, especially F2 or worse, in PBC, suggesting that At-PI can correctly diagnose fibrosis regardless of hepatic inflammation.

  • Open Access

    Ultrasound-Guided Attenuation Parameter Is Useful for Quantifying Hepatic Steatosis in Nonalcoholic Steatohepatitis

    by Yu Ogino, Noritaka Wakui, Hidenari Nagai, Yoshinori Igarashi

    Background: The number of patients with nonalcoholic fatty liver disease has been steadily increasing, and around 10%-20% of these patients are classified as having nonalcoholic steatohepatitis (NASH). The first step to identifying patients with NASH is assessing for hepatic steatosis, which is commonly done noninvasively by ultrasound examination. However, conventional methods are not always effective at lower levels of steatosis. Thus, we sought to determine the utility of a new method using the ultrasound-guided attenuation parameter (UGAP) for quantifying hepatic steatosis in NASH.Methods: Subjects were 36 patients with NASH (20 men, 16 women; mean age 56 [37 to 73] years) who underwent liver biopsy and ultrasonography using a GE LOGIQ E9 system and C1-6 probe at our hospital between 2017 and 2020. B-Mode imaging of segment V in the liver was acquired and echo attenuation was assessed using UGAP. Steatosis score (S0: Results: Steatosis score was S0 in 4 patients, S1 in 16, S2 in 10, and S3 in 6. AC by steatosis score was 0.54 ± 0.06, 0.63 ± 0.05, 0.74 ± 0.05, and 0.79 ± 0.05 dB/cm/MHz for S0, S1, S2, and S3, respectively. AC by UGAP differed significantly between S0 and S2 (p < 0.05), S0 and S3 (p < 0.05), S1 and S2 (p < 0.01), and S1 and S3 (p < 0.01), demonstrating a significant increase with steatosis score. Receiver operating characteristic analysis showed good diagnostic performance of UGAP for patients with steatosis score ≥1, ≥2, and ≥3 (AUROC = 0.95, 0.96, and 0.93, respectively). Liver fat content (%) from liver specimens and AC (r = 0.83, p < 0.01) showed a significant positive correlation.Conclusions: UGAP is useful for quantifying hepatic steatosis in patients with NASH.

  • Open Access

    A patient with advanced hepatocellular carcinoma and portal vein tumor thrombosis who showed a complete response to lenbatinib despite the complication of destructive thyroiditis

    by Kojiro Kobayashi, Hidenari Nagai, Takanori Mukozu, Daigo Matsui, Teppei Matsui, Naoyuki Yoshimine, Makoto Amanuma, Yu Ogino, Yasuko Daido, Noritaka Wakui, et al.

    80歳台女性.右背部痛に対する腹部単純CT検査にて,肝右葉を占める巨大腫瘤を指摘され,当科へ紹介となった.各種画像検査の結果から,門脈本幹への浸潤を伴うportal vein tumor thrombosis(PVTT)を合併した巨大肝細胞癌(HCC)と診断し,lenvatinibを用いて治療を開始した.lenvatinib投与開始2カ月後の採血で,急激な血中free T3およびfree T4の上昇を認め,破壊性甲状腺炎と診断しthiamazole内服を開始した.その後甲状腺機能低下へ移行したのを確認し,thiamazoleからlevothyroxine sodium hydrateへ変更することにより甲状腺機能が正常化し,さらに腹部造影CT検査でHCCの縮小壊死を確認した.lenvatinibが破壊性甲状腺炎を誘発し,PVTT合併HCCに対して著効した例は貴重であると考え報告する.